Skip to main content

letter

. 1995 Nov 18;311(7016):1372–1373. doi: 10.1136/bmj.311.7016.1372

Decision analysis and screening for Down's syndrome. Costs were overestimated.

PMCID: PMC2551271 PMID: 7496309

1372

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

Dawson A. J., Jones G., Matharu M. S., Reynolds T. M., Penney M. D., John R., Creasy M., Gregory P. Serum screening for Down's syndrome. Br J Obstet Gynaecol. 1993 Sep;100(9):875–877. doi: 10.1111/j.1471-0528.1993.tb14326.x. [DOI] [PubMed] [Google Scholar]
Fletcher J., Hicks N. R., Kay J. D., Boyd P. A. Using decision analysis to compare policies for antenatal screening for Down's syndrome. BMJ. 1995 Aug 5;311(7001):351–356. doi: 10.1136/bmj.311.7001.351. [DOI] [PMC free article] [PubMed] [Google Scholar]
Reynolds T. M., Nix A. B., Dunstan F. D., Dawson A. J. Age-specific detection and false-positive rates: an aid to counseling in Down syndrome risk screening. Obstet Gynecol. 1993 Mar;81(3):447–450. [PubMed] [Google Scholar]
Reynolds T., John R., Spencer K. Utility of unconjugated estriol in screening for Down syndrome is not proven. Clin Chem. 1993 Sep;39(9):2023–2026. [PubMed] [Google Scholar]
Spencer K., Coombes E. J., Mallard A. S., Ward A. M. Free beta human choriogonadotropin in Down's syndrome screening: a multicentre study of its role compared with other biochemical markers. Ann Clin Biochem. 1992 Sep;29(Pt 5):506–518. doi: 10.1177/000456329202900504. [DOI] [PubMed] [Google Scholar]

ACTIONS

RESOURCES